A Study of IDP-001 in Advanced or Metastatic Solid Tumors

Part of paid clinical trials in Edison, New Jersey.

Sponsor
InduPro, Inc.
Study ID
NCT07602842
Phase
PHASE1/PHASE2
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • IDP-001 — DRUG
    IV infusion

Study Details

This clinical study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of IDP-001 in participants with advanced or metastatic squamous and non-squamous NSCLC and other squamous cell solid tumors (for example, head and neck, esophageal, cervical, cutaneous).

Key Dates

Start date
Jun 30, 2026
Status verified
May 2026
Primary completion
Jun 30, 2028
Completion
Dec 31, 2028

Study Design

Enrollment
132 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: Phase 1 Part 1 Dose Escalation
    Participants with advanced or metastatic solid tumors will receive IDP-001 as intravenous (IV) infusion.
  • Experimental: Phase 1 Part 2 Indication Selection
    Participants with a single tumor indication will receive IDP-001 as IV infusion

Primary Outcome Measure

Phase 1 Part 1: Number of Participants with Dose Limiting Toxicities (DLTs) during Cycle 1 [ Time Frame: 3 weeks ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Hackensack Meridian - John Theurer Cancer CenterEdisonNew Jersey08837
Miguel Gonzalez Velez, M.D.
480-232-2015

Find similar trials in Edison, NJ

Related Studies